Observe The Safety And Efficacy Of Different Dose Of Tirofiban Inhibitor On Acute STEMI PCI Of Patients

Objective:The effect of different dose of domestic GPIIb/IIIa inhibitor (tirofiban) onbleeding, ischemic events and thrombocytopenia was observated and analyzed in order to findthe efficacy and safety of low-dose domestic GPIIb/IIIa inhibitor on acute STEMI PCI patients.Methods:Object of study:127patients with acute STEMI who receive direct PCItreatment were researched during2012and divided into two groups: one was the experimentalgroup (low-dose, n=65) and the other was the control group (recommended-dose group,n=62).Medication: Two groups of patients received aspirin300mg and clopidogrel300mgbefore the operation, made clear IRA by coronary angiography, tirofiban was applied after sealwire or balloon through pathological changes, all patients was injected tirofiban0.5mg (10ml)at twice in coronary artery around canalizing IRA, then followed by infusion at a rate of0.12μg/kg/min of the experimental group and0.15μg/kg/min of the control group through pump to36h.Heparin was used in PCI procedure at100U/kg,all patients was injected novartis heparinsodium80mg/d after6hours of PCI procedure. The ejection fraction, which is suggested bythe cardiac ultrasound after48hours of PCI procedure, is analyzed.Bleeding,isehemic events,thrombocytopenia and MACE were observed and analyzed during hospitalization.Statisticanalysis:Data were analyzed by the SPSS17.0for windows. P<0.05was considered to bestatistically significant.Results:(1)Two groups total bleeding events in comparison, no statistical difference (P=0.260).(2)Ischemic events two groups, there was no statistically significant difference (P=0.430).(3)In the comparison of thrombocytopenia, two groups is no statistical difference (P=0.488).(4)Two groups of patients before and after dosing platelet count change no statisticaldifference (P=0.359, P=0.390).(5)Left ventricular ejection fraction, two groups has no statistical difference (P=0.438).Conclusions:(1)Using different doses for class had no direct influence patient’s plateletcount and platelet reduce the incidence of events.(2)Reduce the class had dose not increase therisk of PCI postoperative ischemia, deaths, and not increase the deterioration degree of cardiacfunction during PCI perioperative period.(3)Appropriate reduce for class dose may have hadbleeding tendency, but did not reduce the total incidence of bleeding events.(4)Appropriatereduce doses of tirofiban for PCI treatment is safe and effective in patients with acute STEMI.